ABSTRACT
Since the fast expansion of living donor liver transplantation (LDLT) over last few decades, small-for-size syndrome (SFSS) has emerged as a tough problem. Herein the first case of LDLT combined hemi-portocaval shunt in the mainland of China was reported. Portal venous over perfusion was well modulated and the recipient recovered uneventfully. LDLT combined hemi-portocaval shunt was a feasible procedure for preventing SFSS in LDLT.
Subject(s)
Adult , Humans , Male , Carcinoma, Hepatocellular , General Surgery , Liver Neoplasms , General Surgery , Liver Transplantation , Methods , Living Donors , Portacaval Shunt, Surgical , MethodsABSTRACT
Stem cells possess unlimited self-renewal properties and the ability to produce multiple differentiation progenitors. Mesenchymal stem cells (MSCs) can specifically migrate to multiple kinds of tumors and their metastases in a systemic manner(to all parts of the body). Therefore genetically modified MSCs can serve as vehicle of anticancer factors to inhibit growth of tumor. But many questions remain to be answered and the precise mechanisms remain unclear. This paper reviews the mechanism of MSC homing, MSCs as delivery vectors for cancer therapy and its advantages over traditional drug vehicle. MSCs as delivery vectors can be used for cellular therapy in future cancer treatment.
ABSTRACT
Stem cells possess unlimited self-renewal properties and the ability to produce multiple differentiation progenitors. Mesenchymal stem cells (MSCs) can specifically migrate to multiple kinds of tumors and their metastases in a systemic manner(to all parts of the body). Therefore genetically modified MSCs can serve as vehicle of anticancer factors to inhibit growth of tumor. But many questions remain to be answered and the precise mechanisms remain unclear. This paper reviews the mechanism of MSC homing, MSCs as delivery vectors for cancer therapy and its advantages over traditional drug vehicle. MSCs as delivery vectors can be used for cellular therapy in future cancer treatment.